Investment Rating - The report maintains a "Strong Buy" investment rating for the company [2][6]. Core Views - The company is expected to enhance its profitability through both organic growth and external collaboration, positioning itself as a key platform for capital operations and international business expansion under China Tobacco's high-quality development strategy [6][8]. - Revenue for 2024 is projected to reach 13.07 billion HKD, reflecting a year-on-year growth of 10% [6]. - The company has shown robust growth in its import and export business, particularly in tobacco leaf and cigarette exports, with significant increases in both revenue and profit margins [6][8]. Financial Data and Valuation - Total revenue is forecasted to grow from 11.84 billion HKD in 2023 to 17.21 billion HKD by 2027, with a compound annual growth rate (CAGR) of approximately 8% [6][8]. - The net profit attributable to shareholders is expected to rise from 599 million HKD in 2023 to 1.23 billion HKD in 2027, with a notable growth rate of 14% in 2025 [6][8]. - Earnings per share (EPS) are projected to increase from 0.87 HKD in 2023 to 1.77 HKD in 2027, indicating a strong upward trend in profitability [6][8]. Key Financial Ratios - The company’s return on equity (ROE) is expected to remain strong, with a forecast of 28.4% in 2024, slightly decreasing to 24.6% by 2027 [8]. - The debt-to-asset ratio is projected to rise from 60% in 2023 to 69.3% in 2025, indicating a potential increase in leverage [8]. - The price-to-earnings (PE) ratio is expected to decrease from 28.0 in 2023 to 13.6 by 2027, suggesting an attractive valuation as earnings grow [8].
中烟香港（06055）：盈利能力提升，内生外延协同发力